Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypophosphataemic rickets after ifosfamide treatment in children.

Literature DB >> 2503116

Hypophosphataemic rickets after ifosfamide treatment in children.

R Skinner¹, A D Pearson, L Price, K Cunningham, A W Craft.

Abstract

Entities: Chemical Species

Mesh：

Substances：
Phosphates
Ifosfamide

Year: 1989 PMID： 2503116 PMCID： PMC1836803 DOI： 10.1136/bmj.298.6687.1560

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

4 in total

1. Unexpected toxicity in patients treated with iphosphamide.

Authors: J J Van Dyk; H C Falkson; A M Van der Merwe; G Falkson
Journal: Cancer Res Date: 1972-05 Impact factor: 12.701

2. Renal dysfunction after treatment with isophosphamide (NSC-109724).

Authors: R A DeFronzo; M Abeloff; H Braine; R L Humphrey; P J Davis
Journal: Cancer Chemother Rep Date: 1974 May-Jun

3. A phase II study of ifosfamide in children with recurrent solid tumours.

Authors: C R Pinkerton; H Rogers; C James; A Bowman; P R Barbor; O B Eden; J Pritchard
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

4. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.

Authors: G Sangster; S B Kaye; K C Calman; J F Dalton
Journal: Eur J Cancer Clin Oncol Date: 1984-03

4 in total

15 in total

Review 1. Childhood cancer: cure at what cost?

Authors: P H Morris-Jones; A W Craft
Journal: Arch Dis Child Date: 1990-06 Impact factor: 3.791

Review 2. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors: K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal: Drugs Date: 1991-09 Impact factor: 9.546

Hypophosphataemic rickets after ifosfamide treatment in children.

1. Unexpected toxicity in patients treated with iphosphamide.

2. Renal dysfunction after treatment with isophosphamide (NSC-109724).

3. A phase II study of ifosfamide in children with recurrent solid tumours.

4. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.

Review 1. Childhood cancer: cure at what cost?

Review 2. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

3. Iphosphamide-induced nephrotoxicity in children.

4. Hypophosphatemic rickets after ifosfamide treatment.

Review 5. Renal toxicity and chemotherapy in children with cancer.

Review 6. Cytostatics--induced tubular toxicity.

Review 7. Assessment of chemotherapy-associated nephrotoxicity in children with cancer.

8. Nephrotoxicity after ifosfamide.

9. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Review 10. Dosing and side-effects of ifosfamide plus mesna.